Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.60
NAS:XOMA's Cash-to-Debt is ranked lower than
85% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. NAS:XOMA: 0.60 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:XOMA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 1.25 Max: 68.89
Current: 0.6
0.17
68.89
Equity-to-Asset -1.65
NAS:XOMA's Equity-to-Asset is ranked lower than
97% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NAS:XOMA: -1.65 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:XOMA' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.65  Med: -0.01 Max: 0.48
Current: -1.65
-1.65
0.48
Piotroski F-Score: 1
Altman Z-Score: -63.60
Beneish M-Score: -9.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -1106.36
NAS:XOMA's Operating Margin % is ranked lower than
77% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. NAS:XOMA: -1106.36 )
Ranked among companies with meaningful Operating Margin % only.
NAS:XOMA' s Operating Margin % Range Over the Past 10 Years
Min: -1106.36  Med: -117.91 Max: 13.17
Current: -1106.36
-1106.36
13.17
Net Margin % -962.08
NAS:XOMA's Net Margin % is ranked lower than
77% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. NAS:XOMA: -962.08 )
Ranked among companies with meaningful Net Margin % only.
NAS:XOMA' s Net Margin % Range Over the Past 10 Years
Min: -962.08  Med: -134.79 Max: 0.56
Current: -962.08
-962.08
0.56
ROA % -121.98
NAS:XOMA's ROA % is ranked lower than
87% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:XOMA: -121.98 )
Ranked among companies with meaningful ROA % only.
NAS:XOMA' s ROA % Range Over the Past 10 Years
Min: -121.98  Med: -51.27 Max: 0.92
Current: -121.98
-121.98
0.92
ROC (Joel Greenblatt) % -3176.43
NAS:XOMA's ROC (Joel Greenblatt) % is ranked lower than
74% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. NAS:XOMA: -3176.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:XOMA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3269.63  Med: -425.1 Max: 46.51
Current: -3176.43
-3269.63
46.51
3-Year Revenue Growth Rate -51.60
NAS:XOMA's 3-Year Revenue Growth Rate is ranked lower than
84% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. NAS:XOMA: -51.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:XOMA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -60.8  Med: -21.3 Max: 148.1
Current: -51.6
-60.8
148.1
3-Year EBITDA Growth Rate -32.90
NAS:XOMA's 3-Year EBITDA Growth Rate is ranked lower than
84% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. NAS:XOMA: -32.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:XOMA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -49.3  Med: -26.3 Max: 31
Current: -32.9
-49.3
31
3-Year EPS without NRI Growth Rate -32.30
NAS:XOMA's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:XOMA: -32.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:XOMA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.4  Med: -18.6 Max: 35
Current: -32.3
-52.4
35
GuruFocus has detected 4 Warning Signs with XOMA Corp $NAS:XOMA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:XOMA's 10-Y Financials

Financials (Next Earnings Date: 2017-06-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

XOMA Guru Trades in

XOMA Guru Trades in

Q3 2016

XOMA Guru Trades in Q3 2016

Jim Simons 193,095 sh (New)
Paul Tudor Jones 30,725 sh (New)
» More
Q4 2016

XOMA Guru Trades in Q4 2016

Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with XOMA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BDSI, NAS:CASC, AMEX:BTX, NAS:BSTC, NAS:ANIP, NAS:BCRX, NAS:BMRN » details
Traded in other countries:X0M1.Germany,
XOMA Corp discovers and develops antibody-based therapeutics. Several of its antibodies have properties due to their interaction at allosteric sites on specific protein rather than the orthosteric, or active sites.

XOMA Corp was incorporated in Delaware in 1981 and became a Bermuda-exempted company in December 1998. The Company discovers and develops antibody-based therapeutics. Several of its antibodies have properties due to their interaction at allosteric sites on specific protein rather than the orthosteric, or active sites. The compounds are designed to either enhance or diminish the protein's activity as desired. Its lead product candidate, gevokizumab, is a proprietary potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). It is also developing XOMA 3AB, a combination, or cocktail, of antibodies designed to neutralize the most potent of botulinum toxins. Its geographic segments include United States, Europe, and Asia Pacific. The Company's competitors include AbbVie Inc., Biovitrum AB, Allergan, Novartis AG, pSivida, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., and Emergent BioSolutions, Inc. In addition to regulations in the United States, the Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of any future products.

Top Ranked Articles about XOMA Corp

Xoma Stock Tumbles 3.81% After Earnings Release The company was one of the top gainers last week, and investors expected it to report a rise in EPS
Xoma Corp. (NASDAQ:XOMA) stock rose 26% by the end of last week as investors eagerly awaited the company's latest earnings report. Read more...

Ratios

vs
industry
vs
history
PS Ratio 7.67
XOMA's PS Ratio is ranked higher than
65% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. XOMA: 7.67 )
Ranked among companies with meaningful PS Ratio only.
XOMA' s PS Ratio Range Over the Past 10 Years
Min: 0.55  Med: 4.12 Max: 37.15
Current: 7.67
0.55
37.15
Current Ratio 0.84
XOMA's Current Ratio is ranked lower than
90% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. XOMA: 0.84 )
Ranked among companies with meaningful Current Ratio only.
XOMA' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 2.89 Max: 6.32
Current: 0.84
0.84
6.32
Quick Ratio 0.84
XOMA's Quick Ratio is ranked lower than
87% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. XOMA: 0.84 )
Ranked among companies with meaningful Quick Ratio only.
XOMA' s Quick Ratio Range Over the Past 10 Years
Min: 0.84  Med: 2.89 Max: 6.32
Current: 0.84
0.84
6.32
Days Sales Outstanding 31.09
XOMA's Days Sales Outstanding is ranked higher than
75% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. XOMA: 31.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
XOMA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 24.48  Med: 54.2 Max: 226.37
Current: 31.09
24.48
226.37

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.10
XOMA's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. XOMA: -5.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XOMA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -82.3  Med: -14.9 Max: -5.1
Current: -5.1
-82.3
-5.1

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.86
XOMA's Price-to-Median-PS-Value is ranked lower than
78% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. XOMA: 1.86 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
XOMA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 2.15 Max: 22.67
Current: 1.86
0.15
22.67
Earnings Yield (Greenblatt) % -69.79
XOMA's Earnings Yield (Greenblatt) % is ranked lower than
97% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. XOMA: -69.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
XOMA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -74.44  Med: 11 Max: 19.6
Current: -69.79
-74.44
19.6

More Statistics

Revenue (TTM) (Mil) $5.56
EPS (TTM) $ -8.97
Beta2.78
Short Percentage of Float11.55%
52-Week Range $3.96 - 19.00
Shares Outstanding (Mil)6.11

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 10 13 41
EPS ($) -3.25 -1.29 -0.32
EPS without NRI ($) -3.25 -1.29 -0.32
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for XOMA

Headlines

Articles On GuruFocus.com
Xoma Stock Tumbles 3.81% After Earnings Release Mar 17 2017 
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 
XOMA Ltd. Reports Operating Results (10-K) Mar 10 2011 
XOMA Ltd. Reports Operating Results (10-K/A) Dec 27 2010 
XOMA Ltd. Reports Operating Results (10-Q/A) Nov 12 2010 
XOMA Ltd. Reports Operating Results (10-Q) May 06 2010 
XOMA Ltd. Reports Operating Results (10-Q) Aug 06 2009 
XOMA Ltd. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American... Mar 28 2017
XOMA CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or... Mar 27 2017
Idera Pharmaceuticals and XOMA Find Paths to Financial Growth Mar 23 2017
XOMA Announces Four Presentations at the 2017 ENDO Meeting Mar 23 2017
XOMA CORP Financials Mar 22 2017
XOMA CORP Files SEC form 8-K, Other Events Mar 22 2017
XOMA Announces Full Repayment of Hercules Technology Growth Capital Debt Obligation Mar 22 2017
Xoma Stock Tumbles 3.81% After Earnings Release Mar 17 2017
Xoma reports 4Q loss Mar 16 2017
Xoma reports 4Q loss Mar 16 2017
XOMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 16 2017
Q4 2016 XOMA Corp Earnings Release - Before Market Open Mar 16 2017
XOMA Reports Fourth Quarter and Full Year 2016 Financial Results Mar 16 2017
XOMA to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call... Mar 14 2017
XOMA CORP Files SEC form 8-K, Change in Directors or Principal Officers Mar 08 2017
XOMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Mar 06 2017
XOMA to Present New Strategic Initiatives at the Cowen and Company 37th Annual Health Care... Feb 28 2017
XOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to... Feb 16 2017
XOMA Appoints Matthew Perry to its Board of Directors Feb 16 2017
Biotech Industry Poised for a Breakout in 2017? Today's Reports on Cellect Biotechnology and XOMA Feb 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)